CA2352611A1 - Compositions a base de 2-hydroxymethylolanzapine et leurs utilisations - Google Patents

Compositions a base de 2-hydroxymethylolanzapine et leurs utilisations Download PDF

Info

Publication number
CA2352611A1
CA2352611A1 CA002352611A CA2352611A CA2352611A1 CA 2352611 A1 CA2352611 A1 CA 2352611A1 CA 002352611 A CA002352611 A CA 002352611A CA 2352611 A CA2352611 A CA 2352611A CA 2352611 A1 CA2352611 A1 CA 2352611A1
Authority
CA
Canada
Prior art keywords
hydroxymethylolanzapine
pharmaceutically acceptable
disorder
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002352611A
Other languages
English (en)
Inventor
William E. Yelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2352611A1 publication Critical patent/CA2352611A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Abstract

La présente invention concerne des compositions et des méthodes faisant intervenir le composé 2-hydroxyméthylolanzapine pour le traitement de la psychose chez l'homme. Le composé 2-hydroxyméthylolanzapine se caractérise par une interaction médicamenteuse moindre que l'olanzapine et autorise un schéma posologique plus prévisible que cette dernière substance. La 2-hydroxyméthylolanzapine convient également pour le traitement des pathologies suivantes : manie aiguë, états anxieux légers, schizophrénie, troubles bipolaires, hyperactivité avec déficit de l'attention, troubles de l'autisme, hyperagressivité, abus de substances psychoactives, signes et symptômes de dépression, tics, troubles intestinaux fonctionnels et mycose cutanée.
CA002352611A 1998-11-23 1999-11-22 Compositions a base de 2-hydroxymethylolanzapine et leurs utilisations Abandoned CA2352611A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10955298P 1998-11-23 1998-11-23
US60/109,552 1998-11-23
PCT/US1999/027640 WO2000030648A1 (fr) 1998-11-23 1999-11-22 Compositions a base de 2-hydroxymethylolanzapine et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2352611A1 true CA2352611A1 (fr) 2000-06-02

Family

ID=22328269

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002352611A Abandoned CA2352611A1 (fr) 1998-11-23 1999-11-22 Compositions a base de 2-hydroxymethylolanzapine et leurs utilisations

Country Status (6)

Country Link
US (2) US6174882B1 (fr)
EP (1) EP1133299A1 (fr)
JP (1) JP2002530339A (fr)
AU (1) AU757874B2 (fr)
CA (1) CA2352611A1 (fr)
WO (1) WO2000030648A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
RU2322985C2 (ru) * 2001-02-15 2008-04-27 Хитиям, Инк. Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
WO2004010932A2 (fr) * 2002-07-30 2004-02-05 Peter Migaly Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
CA2511619C (fr) 2002-12-27 2011-07-12 Otsuka Pharmaceutical Co., Ltd. Derives de carbostyrile et inhibiteurs de reabsorption de serotonine pour le traitement des troubles de l'humeur
US7763660B2 (en) * 2003-02-05 2010-07-27 The University Of Vermont And State Agricultural College Inhibitors of Candida albicans
JP2008524332A (ja) 2004-12-20 2008-07-10 コレジウム ファーマシューティカル， インク． 睡眠傷害のための医薬組成物
WO2006081327A2 (fr) * 2005-01-25 2006-08-03 University Of Vermont And State Agricultural College Petites molecules limitant la croissance fongique
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
WO2009014770A2 (fr) 2007-02-01 2009-01-29 Green Alan I Combinaisons de blocage des récepteurs dopaminergiques d2 avec inhibition de la recaptation de la norépinéphrine et blocage des récepteurs de norépinéphrine alpha 2
AU2008254585B2 (en) * 2007-05-21 2013-09-26 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5627178A (en) 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US5457101A (en) 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
JPH11512705A (ja) 1995-09-29 1999-11-02 イーライ・リリー・アンド・カンパニー チック症を処置する方法
WO1997023221A1 (fr) * 1995-12-21 1997-07-03 Eli Lilly And Company Methode de traitement de dermatites
IL125031A0 (en) 1995-12-22 1999-01-26 Lilly Co Eli Method for treating depression
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
TR199801797T2 (xx) 1996-03-11 1998-12-21 Eli Lilly And Company �ki kutuplu bozukluk tedavisi.
JP2000517287A (ja) * 1996-03-11 2000-12-26 イーライ・リリー・アンド・カンパニー 物質乱用の処置方法
CZ290498A3 (cs) * 1996-03-11 1999-10-13 Eli Lilly And Company Farmaceutický prostředek proti autistickým stavům
GB9615767D0 (en) 1996-07-26 1996-09-04 Smithkline Beecham Plc Novel treatment
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
WO1999059593A1 (fr) * 1998-05-21 1999-11-25 Eli Lilly And Company Therapie combinee destinee au traitement de la depression
PL344331A1 (en) * 1998-05-22 2001-11-05 Lilly Co Eli Combination therapy for treatment of refractory depression
WO1999061014A2 (fr) * 1998-05-28 1999-12-02 Sepracor Inc. Compositions et methodes utilisant de la r(-) fluoxetine et d'autres ingredients actifs
BR9911068A (pt) * 1998-05-29 2001-02-06 Lilly Co Eli Terapia combinada para tratamento de distúrbios bipolares

Also Published As

Publication number Publication date
US6174882B1 (en) 2001-01-16
US6346528B1 (en) 2002-02-12
EP1133299A1 (fr) 2001-09-19
AU1631500A (en) 2000-06-13
JP2002530339A (ja) 2002-09-17
AU757874B2 (en) 2003-03-06
WO2000030648A1 (fr) 2000-06-02

Similar Documents

Publication Publication Date Title
DE69921157T2 (de) Verwendungsmethoden und zusammenstellungen die einen dopaminewiederaufnahmeinhibitor enthalten
KR100704319B1 (ko) 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
AU757874B2 (en) 2-hydroxymethylolanzapine compositions and methods
AU756468B2 (en) Combination therapy for treatment of bipolar disorders
AU757870B2 (en) Pharmaceutical compositions containing olanzapine-N-oxide
AU757973B2 (en) Desmethylolanzapine compositions and methods
AU4008699A (en) Combination therapy for treatment of refractory depression
WO2015089111A1 (fr) Nouveaux procédés
CZ295776B6 (cs) Opticky čistý (+)-norcisaprid pro léčení gastroesofageálního refluxu
PL197981B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
PL197982B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
PL197984B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued